gms | German Medical Science

62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

07. - 11. Mai 2011, Hamburg

Expression and up-regulation of coagulation factors and their receptors in tumor tissue and peripheral blood of patients with cerebral carcinoma metastases

Meeting Abstract

Suche in Medline nach

  • S. Kuhn - Neurochirurgische Klinik, Klinikum der Friedrich-Schiller-Universität, Jena, Deutschland
  • L. Handel - Neurochirurgische Klinik, Klinikum der Friedrich-Schiller-Universität, Jena, Deutschland
  • S. Frank - Neurochirurgische Klinik, Klinikum der Friedrich-Schiller-Universität, Jena, Deutschland
  • R. Kalff - Neurochirurgische Klinik, Klinikum der Friedrich-Schiller-Universität, Jena, Deutschland

Deutsche Gesellschaft für Neurochirurgie. Polnische Gesellschaft für Neurochirurgen. 62. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgen (PNCH). Hamburg, 07.-11.05.2011. Düsseldorf: German Medical Science GMS Publishing House; 2011. DocMI.03.03

DOI: 10.3205/11dgnc190, URN: urn:nbn:de:0183-11dgnc1900

Veröffentlicht: 28. April 2011

© 2011 Kuhn et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Patients with malignant neoplasias often suffer from thromboembolic events that complicate the course of cancer disease and reduce the patients’ quality of life or shorten the survival time.

Methods: Twenty tumor samples of intracerebral metastases of clear-cell renal cell carcinomas, small cell carcinomas of the lung and malignant melanomas were investigated immunohistochemically for the expression of the coagulation factors II/IIa and X/Xa as well as for the expression of the protease-activated receptors type 1, 2, 3, and 4. In addition, 116 patients with intracranial tumors were prospectively included in a case-controlled study and correlated to 116 control patients with lumbar disc herniations. Their blood was collected one day before and one and four days after the cranial metastasis surgery and investigated for the activity of the coagulation factors II, V, VII, VIII, IX, X, XI, XII, and XIII as well as for the activity of antithrombin III, and the concentrations of the d-dimers and of fibrinogen.

Results: Here, we show that even patients without active peripheral tumor disease, but with symptomatic brain metastasis develop a systemic activation of multiple coagulation factors. The pro-coagulatory state is expressed preoperatively, but can also be observed in the early postoperative period. The activity of antithrombin III is enhanced in patients with brain metastases, whereas the concentrations of fibrinogen or d-dimers do not significantly differ from the control group. In addition, intracerebral metastases of clear-cell renal cell carcinomas, small cell carcinomas of the lung, and malignant melanomas express prothrombin, thrombin, the coagulation factor X, and the protease-activated receptors type 1, 2, 3, and 4.

Conclusions: This study shows for the first time that human brain metastases express coagulation factors and their receptors and patients with intracerebral brain metastases demonstrate a systemic activation of the coagulation system.